Kornimate/medical-research-clean huggingface dataset:
offering routine and rapid point of care (poc) syphilis testing in pregnant patients presenting to the emergency department

Conditions: Syphilis

Summary: the purpose of this study is to offer routine lab-based and rapid point of care (poc) syphilis diagnostic testing in the emergency department (ed) and obstetrical (ob) triage , thereby increasing screening and treatment initiation for pregnant patients without prenatal care or with no documented syphilis results during the index pregnancy in other to increase rates of full treatment to determine if the implementation of a robust linkage to care program for pregnant patients with positive rapid poc results will more likely result in complete treatment for all stages of syphilis and adherence to recommended maternal and newborn longitudinal follow up and to assess factors that contribute to treatment completion after implementation of the intervention will also be analyzed to tailor efforts targeting social and healthcare navigation factors that affect health equity; including poverty, insurance, health literacy and others.


Eligibility criteria:
inclusion criteria: * pregnant individuals that are seeking care at university of texas, memorial herman and lyndon b johnson sites ed or obstetrical triage units. * no prenatal care during index pregnancy * no documented syphilis result during the index pregnancy exclusion criteria: * pregnant individuals with documented care and syphilis results in the index pregnancy for specific trimester as mandated by texas law

Keywords: syphilis diagnostic testing pregnancy
promoting long-term behavior change to reduce cvd risk

Conditions: Obesity

Summary: once intervention class or staff contact is removed, obese adults participating in behavioral weight-loss programs often give up healthy eating habits and regain weight. we examined whether taste-based goal setting, which minimizes perceived deprivation by promoting taste and moderation, would sustain long-term reductions in saturated fat and body mass index (bmi).

once intervention class or staff contact is removed, obese adults participating in behavioral weight-loss programs often give up healthy eating habits and regain weight. we examined whether taste-based goal setting, which minimizes perceived deprivation by promoting taste and moderation, would sustain long-term reductions in saturated fat and body mass index (bmi). participants were randomized to taste-based choices (taste-based goal setting + a standard 6-month behavioral weight-loss intervention), smart consumers (a standard 6-month intervention alone) or community access (access to commercial/community-based behavioral weight-loss programs) and followed over 18 months. to test our hypotheses, we examined a set of orthogonal contrasts (tbc and sc vs. ca; tbc vs. sc) on reductions in saturated fat (block ffq) and clinic-measured bmi.

Eligibility criteria:
inclusion criteria:- body mass index between 27-37 * physically inactive * able to participate in physical activity * percentage of daily calories from total fat 30% or more * free of diagnosed heart disease * stable on medications for 3 months or more exclusion criteria:- diabetic * dysphoric (beck depression inventory score greater than 18) * binge eating or bulimic (eating disorder diagnostic scale)
collaborative care intervention for cancer patients and their family caregivers -lite

Conditions: Cancer; Depression; Fatigue; Pain; Sleep

Summary: to test the efficacy of a web-based stepped collaborative care intervention to reduce symptoms of depression, pain, and fatigue and improve health-related quality of life (hrql) in advanced cancer patients and to reduce stress and depression, and fewer cvd risk factors in caregivers.

the intervention is designed to maintain quality of life for those in greatest need and least access to resources. this innovative and scalable web-based collaborative care intervention is expected not only to improve patients' quality of life, at the end of life, but also reduce caregiver stress and depression, and potentially health morbidity and mortality of patients and spousal and intimate partner caregivers from socioeconomically disadvantaged backgrounds. study findings are expected to lead to research examining the dissemination and implementation of the intervention.

Eligibility criteria:
inclusion criteria: * patients: biopsy and/or radiograph proven diagnosis of hepatocellular carcinoma, cholangiocarcinoma, gallbladder carcinoma or breast, ovarian, or colorectal cancer with liver metastases with a life expectancy of at least one year; age \>21 years; no evidence of thought disorder, delusions, or active suicidal ideation is observed or reported. * caregivers: a spouse or cohabitating intimate partner of an advanced cancer patient being evaluated the upmc's liver cancer center and age \>21 years exclusion criteria: * patients: age \< 21 years, lack of fluency in english, evidence of thought disorder, delusions, hallucinations, or suicidal ideation. * caregivers: age \< 21 years, lack of fluency in english, evidence of thought disorder, delusions, hallucinations, or suicidal ideation.

Keywords: cancer depression fatigue pain
efficacy of biological therapy in pediatric inflammatory bowel disease

Conditions: Effect of Drug

Summary: compare efficacy of different biologicals in induction of remission including clinical, laboratory and histopathological remission.

ibd are multifactorial disorders characterized by chronic relapsing intestinal inflammation (fousekis et al .,2021). main subtypes of pediatric ibd are crohn's disease (cd), ulcerative colitis (uc), and ibd unclassified (corica \& romano .., 2017) mechanism of ibd involves uncontrolled immune mediated inflammatory response in genetically predisposed individuals to an unknown environmental trigger that interacts with gut microbiome and primarily affects gastrointestinal tract ( iyer \& corr ..,2021) pediatric onset ibd is more aggressive and rapidly progressive disease compared to adult onset ibd. nearly a quarter of all patients with ibd develop this disease during childhood (moon .., 2019), mean age at diagnosis ranged from 4.5 to 16 years in pediatric cases (mosli et al ..,2021) rates of pediatric onset ibd continue to rise around the world (kuenzig et al ..,2022 ). in2018, the highest annual incidences of pediatric ibd were 23/100000 person in europe, 15.2/100000 in north america, and 11.4/100000 in asia/ middle east and oceania (sýkora et al .., 2018) pediatric ibd management and therapeutic approach can be chall enging, especially in younger patients (romeo et al .., 2020 )). biologic agents have revolutionized the treatment paradigm of pediatric ibd (kapoor \& crowley ..,2021) biological drugs are monoclonal antibodies target specific cytokines involved in inflammatory cascade, such as tumour necrosis factor alpha (tnfα), integrins or interleukin 12/23, and have been approved for both pediatric cd and uc (romeo et al 2020)

Eligibility criteria:
inclusion criteria: patients fulfilling modified porto criteria for diagnosis of ibd including clinical features, laboratory, radiological and pathological findings. patients initially severely diseased or in relapse and planned to start or change biological therapy. exclusion criteria: patients already on biological therapy and controlled. patients with known humeral or cell mediated immunodeficiency. ethical

Keywords: biological therapy , ibd
ak104 combined with chemotherapy as neoadjuvant treatment for advanced ovarian cancer

Conditions: Ovarian Cancer

Summary: previous studies have suggested that immunotherapy combined with chemotherapy as neoadjuvant treatment for ovarian cancer may have a synergistic effect and a manageable safety profile. ak104 is a bispecific antibody targeting pd-1 and ctla-4. therefore, this study aimed to evaluate the efficacy and safety of ak104 combined with chemotherapy as the neoadjuvant treatment for advanced ovarian cancer.


Eligibility criteria:
key inclusion criteria: - 1. woman ≥ 18 and ≤ 75 years old on day of signing informed consent. 2. eastern cooperative oncology group (ecog) performance status of 0 or 1. 3. advanced figo stage iii to iv patient not able to receive primary debulking surgery for which neo adjuvant chemotherapy is recommended. 4. have at least one measurable lesion per recist 1.1 assessed by investigator. 5. have adequate organ function. key exclusion criteria: * 1. histological diagnosis of malignant tumor of non-epithelial origin of the ovary, the fallopian tube or peritoneum or borderline tumor of the ovary. 2. patients with other active malignancies within 5 years prior to enrollment. 3. known active autoimmune diseases. 4. use of immunosuppressive agents within 14 days prior to the first dose of study treatment. 5. presence of other uncontrolled serious medical conditions.
outcome of dental implant therapy in patients treated with antiresorptive medication

Conditions: Missing Teeth; Implants; Cancer; Osteoporosis

Summary: aim of the study is to examine the feasibility of dental implant insertion in patients receiving high, adjuvant and low dose \> 4 years.

the hypothesis of the present study is that dental implant therapy using submerged healing is feasible and predictable in patients receiving high, adjuvant or low dose ar for more than 4 years, as documented by clinical and radiographic signs of osseointegration after 3-4 months, sufficient implant stability for abutment connection, and implant survival rates comparable to those of healthy individuals after one year of prosthetic loading.

Eligibility criteria:
inclusion criteria: * patient with cancer or osteoporosis, treated with antiresorptive treatment. * the patients should have sufficient compliance, this includes willingness to have the planned assessments * the patient should have an expected life span at enrollment of at least 2 years. * the local bone quality and quantity should be sufficient for implant insertion without bone augmentation and is classified according to the classification by cawood \& howell 1988. exclusion criteria: * \> 10 cigarettes daily * hba1c \> 53 mmol/mol * poor oral hygiene * poor general condition: ecog score 3 or 4. * poor prognosis: expected survival \<2 year is an exclusion cause. * presence of metastases of the liver brain. * poor local jaw bone quality acc. to cawood classification stage 3 or 4. * unwillingness to comply with the planned assessments and recordings

Keywords: dental implants high dose antiresorptive medication rehabilitation denosumab bisphosphonate oral rehabilitation adjuvant dose antiresorptive medication low dose antiresorptive medication bone modifying agents
influence of the diversity and composition of the microbiota in the development of pediatric fatty liver

Conditions: Non-Alcoholic Fatty Liver Disease; Obesity; Metabolic Syndrome

Summary: the objectives of the present study are: 1) to identify the intestinal and salivary microbiota associated with the presence and severity of hepatic steatosis in children (study i: case-control study), and 2) to develop a personalized 12-week intervention program based on diet and exercise to examine its effects on the diversity and composition of the microbiota in children with hepatic steatosis (study ii: intervention study)

the microkid project will acts first as a case-control study (study i) in order to identify the hepatic steatosis and intestinal and salivary microbiota in children grouped as non-overweight, obese-non-hepatic steatosis, and obese-hepatic steatosis. then, an intervention study (study ii) will be developed for those children with obesity (i.e., obese-non-hepatic steatosis, and obese-hepatic steatosis groups). methodology: a total of 60 children, 8-12 years-old, will be assigned to control (non-overweight children, n= 20), obese-non-hepatic steatosis (children with obesity, but without hepatic steatosis, n=20), and obese-hepatic steatosis (children with obesity and hepatic steatosis, n= 20) groups (study i: case-control study). the obesity and obesity + hepatic steatosis groups will attend to a 12-weeks healthy lifestyle education program (2 days/month) and home-based exercise program (minimum 3 days/week) (study ii: intervention study). the combined intervention program for the study ii will include: i) healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and ii) exercise program based on high-intensity interval training which combines aerobic and resistance training (at least 3 days/week, from 38 to 44 min). measurements: in the study i (i.e., case-control study), all participants will be evaluated at baseline. for the study ii (i.e., intervention study), only those participants that belongs to obese-non-hepatic steatosis and obese-hepatic steatosis groups, will be additionally evaluated after the intervention program (12-week). the following outcomes will be measured: hepatic fat fraction and abdominal adiposity (magnetic resonance imaging), intestinal and salivary microbiota, body composition (bioimpedance), cardiometabolic risk factors, liver enzymes, physical fitness (field-fitness tests), physical activity (accelerometry), sleep (accelerometry), dietary habits (24h recalls, and food frequency questionnaires), and pubertal development and sociodemographic characteristics will be measured.

Eligibility criteria:
inclusion criteria: * obesity defined based on the sex-and-age specific body mass index standards * 8-12 years old exclusion criteria: * medical conditions that hamper their participation in the exercise program

Keywords: non-alcoholic hepatic steatosis obesity children exercise diet microbiota
il-10 levels and remote ischemic preconditioning in acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: remote ischemic preconditioning has proven beneficial in patients undergoing percutaneous coronary intervention and coronary artery bypass surgery. animal studies suggest remote ischemic preconditioning increases levels of interleukin 10. the investigators aim to determine whether remote ischemic preconditioning results in an increase in il-10 levels in patients following acute myocardial infarction.


Eligibility criteria:
inclusion criteria: - acute myocardial infarction exclusion criteria: - cardiogenic shock active ischemia

Keywords: remote ischemic preconditioning inflammation
a ten-week study evaluating the effectiveness and safety of zoloft in children and adolescents with a diagnosis of ptsd

Conditions: Stress Disorders, Post-Traumatic

Summary: to evaluate the safety and efficacy of sertraline compared to placebo in children and adolescents (6 to 17 years of age) who are outpatients with posttraumatic stress disorder.

this study was terminated on july 11, 2007. the results of the primary endpoint analysis at the interim showed that the zoloft group was not significantly different than the placebo on the primary endpoint and therefore the decision was made to terminate the trial. the decision to terminate the trial was not based on any safety concerns.

Eligibility criteria:
inclusion criteria: * subjects must be from 6 to 17 years of age and will have a maximum age of 17 at the baseline visit of the study. * subjects must have a diagnosis of posttraumatic stress disorder as defined by dsm-iv and determined by the kiddie schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (k-sads-pl). exclusion criteria: * subjects whose trauma is ongoing, or who are living in the same home as their abuser, or who are expected to participate in litigation related to their trauma during the course of the study will be excluded from participation. * subjects who are likely to or are at high risk for experiencing re-exposure to their index trauma.
a study of cardiac safety in patients with her2 positive early breast cancer treated with herceptin

Conditions: Breast Cancer

Summary: this is a single cohort observational safety study. all patients will be treated and monitored according to the local clinical practice. no additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. data will be collected from centre's medical records for up to 5 years or death.


Eligibility criteria:
inclusion criteria: * all patients who are considered candidates to receive herceptin for this indication exclusion criteria: * patients for whom herceptin is contraindicated
prospective evaluation of laparoendoscopic single site versus laparoscopic cholecystectomy

Conditions: Gallbladder Disease

Summary: laparoendoscopic single site cholecystectomy is associated with better cosmetic results and recovery compare to laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * gallbladder disease age: 18-99 exclusion criteria: * intolerance to laparoscopy

Keywords: cholecystectomy gallbladder laparoscopy laparoendoscopic
effect of acitretin versus narrowband ultraviolet b on neopterin level in psoriatic patients .

Conditions: Psoriasis

Summary: to evaluate effect of acitretin versus narrowband uvb on serum level of neopterin in psoriatic patients.


Eligibility criteria:
inclusion criteria: * patients with psoriasis diagnosed clinically aged (15-60). exclusion criteria: * patient with history of skin cancer. * patient with history of photosensitivity. * pregnancy and lactation. * liver failure. * renal failure. * patient with psoriatic artheritis. * patient with allergy to product or any of its components. * patient with poorly controlled dyslipidemia. * patient receiving tetracyclines.
neuroinflammation and cognitive decline in alzheimer disease

Conditions: Alzheimer Disease

Summary: the purpose of this study is to assess the level of neuroinflammation in alzheimer disease subject (mild to moderate) estimated with binding potential (bp) of \[18f\]dpa-714, and its relationship with the kinetics of cognitive decline over a 24-month follow-up period (as assessed by alzheimer's disease assessment scale-cognitive subscale (adas-cog) and mini-mental state examination (mmse) scores).

the purpose of this study is to assess the level of neuroinflammation in alzheimer disease subject (mild to moderate) estimated with binding potential (bp) of \[18f\]dpa-714 , and its relationship with the kinetics of cognitive decline over a 24-month follow-up period (as assessed by adas-cog and mmse scores). (dpa-714 : n,n-diethyl-2-\[4-(2-fluoroethoxy)phenyl\]-5,7-dimethylpyrazolo\[1,5-a\]pyrimidine-3-acetamide)

Eligibility criteria:
inclusion criteria: * informed consent * age more than 50 years (included) * necessary knowledge of french (write and oral) to do neuropsychological tests * study level upper (or equal) than 7 years (considering first year of grammar-school as start) * people with alzheimer disease defined as national institute of neurological and communicative disorders and stroke (nincds) and the alzheimer's disease and related disorders association (adrda) standards : light to mild ad defined by mini-mental state examination (mmse) score between 15 and 25 (included) * social security affiliation. exclusion criteria: * mmse score lower than 15 and upper or equal to 26 * evolutive disease which could possibly had consequences on central nervous system * inflammatory disease or evolutive neoplasia and/or c reactive protein (crp) upper than 10mg/l * chronic use of alchohol and/or drug * serious depression defined by montgomery asberg depression rating scale (madrs) score higher than 18 * surgical or medical condition in the last 3 months * long term treatment which could possibly interfere with inflammatory process (especially the month before pet \[18f\]dpa-714 imaging). * treatment by n-methyl-d-aspartate antagonist * treatment by minocycline * treatment by benzodiazepine (especially the month before pet \[18f\]dpa-714 imaging) (zolpidem, zopiclone and loprazolam excepted) * anomaly at neurological examination which is not a classical symptom * contraindication to magnetic resonance imaging (rmi) * florbetapir\[18f\] hypersensibility * participation to an other experimental protocol with drug. * people under guardianship

Keywords: pet [18f]dpa-714 cognitive decline
anisotropic textile braces for adolescent idiopathic scoliosis

Conditions: Scoliosis

Summary: one of the most common types of 3-dimensional spinal deformities with unknown etiology in youths is adolescent idiopathic scoliosis (ais). the spinal curvature increases as puberty progresses. generally, rigid orthotic bracewear is prescribed as non-invasive treatment for moderate ais if treatment begins early and the orthosis is worn with compliance. obviously, teenage patients are reluctant to accept a rigid orthosis due to aesthetics and the physical constraint. therefore, semi-rigid and flexible orthoses have been developed, but their efficacy is still controversial and there are other issues, such as high pain scores. there is clearly room for improvement. therefore, a garment-type of bracewear will be designed and developed to correct spinal deformity, reduce the possibility of spinal curve progression, and satisfy the needs of the patients as well as take their psychological concerns into consideration.

the design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: 1. axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, 2. 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, 3. pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, 4. derotation between the pelvis and shoulders with uneven straps, and 5. an active mechanism with sensors added to the brace to maintain correct posture.

Eligibility criteria:
inclusion criteria: * aged 10 to 14 years * diagnosis of ais * a cobb's angle between 20 to 30 degrees * a risser grade of the iliac crest of ≤ 2 * pre-menarche or post- menarche by no more than 1 year * ability to read and understand english or chinese * physical and mental ability to adhere to anisotropic textile braces protocol exclusion criteria: * contraindications for x-ray exposure * diagnosis of other musculoskeletal or developmental illness that might be responsible for the spinal curvature * history of previous surgical or orthotic treatment for ais * contraindications for pulmonary and/ or exercise tests * psychiatric disorders * recent trauma * recent traumatic (emotional) event

Keywords: anisotropic textile braces
effect of pantoprazole on the symptoms of acid reflux disease in adult patients (by1023/m3-341)

Conditions: Gastroesophageal Reflux Disease (GERD)

Summary: the aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., request™ questionnaire, patient and investigator assessment). pantoprazole will be administered once daily in the morning at one dose level. the study duration consists of a treatment period of 8 weeks. the study will provide further data on safety and tolerability of pantoprazole.


Eligibility criteria:
main inclusion criteria: * written informed consent * outpatients of at least 18 years (21 years in argentina) * patient considered to have gerd symptoms main exclusion criteria: * acute peptic ulcer and/or ulcer complications * systemic glucocorticoids or non-steroidal anti-inflammatory drugs (nsaids) including cox-2-inhibitors (\> 5 days on demand but not more than 3 consecutive days) during the last 28 days before study start (except regular intake of acetylsalicylic acid at a dose up to 163 mg/day) * intake of proton pump inhibitors during the last 10 days before study start * female patients of childbearing potential not using adequate means of birth control * pregnant or breast-feeding females

Keywords: gastroesophageal reflux disease gerd pantoprazole requesttm